News

Public · Published

TD Cowen maintains Ultragenyx Pharmaceutical at Buy, raises price target to $19 from $18

TD Cowen kept its Buy rating on Ultragenyx Pharmaceutical and raised its price target to $19 from $18. The new target is 5.6% higher and implies 14.3% upside from the November 3 closing price of $16.63.

Published:

Updated:

What happened

TD Cowen kept its Buy rating on Ultragenyx Pharmaceutical and raised its price target to $19 from $18. The new target is 5.6% higher and implies 14.3% upside from the November 3 closing price of $16.63.

Confirmed

Global impact / market context

The higher target signals improved valuation expectations from TD Cowen, but it does not change the company’s reported revenue, costs, or cash available. If investors act on the rating, their buying or selling could influence the share price without changing the business itself.

Analyst inference

Recent analyst views are mixed: the five listed targets range from $16 to $22, while ratings include Buy, Neutral, and Equal-Weight. TD Cowen’s $19 target sits within that range, so its increase is not an across-the-board reassessment.

Confirmed

What to watch

  1. Compare future analyst targets and ratings with TD Cowen’s $19 target; continued differences would show that expectations for Ultragenyx remain divided. Analyst inference
  2. Watch for company updates on revenue, costs, or cash available; those business results could support or weaken the expectations behind analyst valuations. Analyst inference
  3. The article says the $19 target implies 14.3% upside from the November 3 close of $16.63; this is an analyst estimate, not a promised return. Confirmed

Evidence

  • Original source link unavailable